Bottom line: if your week revolves around a GLP-1 dose, this is the tracker built around that week
Then enter the name part of your Kindle email address below
There is also a bigger ongoing study with over 2,000 people to confirm these results and gather more information, which will continue for about 89 weeks
Tirzepatide is a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist a single molecule that activates two separate hormone receptor systems involved in appetite, metabolism, and blood sugar regulation
In that study, tirzepatide was associated with greater average weight loss: People taking the highest dose lost an average of 20.2% of their body weight, compared with 13.7% for those taking semaglutide
We formulated resM to support healthy blood sugar already in the normal range and maintain GLP-1 results